Absci

Update in progress

ABSI (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Absci is a clinical-stage biopharmaceutical company in the United States focused on developing antibody therapeutics. Its programs include ABS-101 in Phase 1 for inflammatory bowel disease; ABS-201, an anti-PRLR antibody in Phase 1/2a for androgenic alopecia; ABS-301 for immuno-oncology; and ABS-501 for oncology. It collaborates with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle, and AMD on joint R&D. Founded in 2011, headquartered in Vancouver, Washington.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive